GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT01918306. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Study identification
- NCT ID
- NCT01918306
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Enrollment
- 11 participants
Conditions and interventions
Conditions
Interventions
- GDC -0941 Drug
- cisplatin Drug
- dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI Procedure
- laboratory biomarker analysis Other
- pharmacological study Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2013
- Primary completion
- Nov 30, 2014
- Completion
- Mar 31, 2015
- Last update posted
- Jun 26, 2017
2013 – 2015
United States locations
- U.S. sites
- 16
- U.S. states
- 16
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | — | — |
| University of California, San Francisco | San Francisco | California | — | — |
| Georgetown University | Washington D.C. | District of Columbia | — | — |
| Emory University | Atlanta | Georgia | — | — |
| University of Chicago | Chicago | Illinois | — | — |
| Indiana University | Indianapolis | Indiana | — | — |
| John Hopkins University | Baltimore | Maryland | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| University of Michigan | Ann Arbor | Michigan | — | — |
| Mayo Clinic | Rochester | Minnesota | — | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | — | — |
| University of North Carolina | Charlotte | North Carolina | — | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | — | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Baylor Breast Center | Houston | Texas | — | — |
| University of Washington | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01918306, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2017 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01918306 live on ClinicalTrials.gov.